A Phase 2 interventional study of Roxadustat in Chronic Kidney Disease, End Stage Renal Disease and Anemia, sponsored by FibroGen. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-01.
Sponsored by FibroGen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing roxadustat in Kidney Failure, Chronic — 2 open to participants now, 3 under way, 1 of them phase 3. roxadustat · Kidney Failure, Chronic.
Among the 15 studies testing roxadustat in Kidney Failure, Chronic, this one is the 15th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 2, and was the 3rd registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →2 of the 15 studies testing roxadustat in Kidney Failure, Chronic are open now, in 1 country. Recruiting first, the newest first:
Mansoura University · Sites in Egypt
Ages 18+
Mansoura University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 7 · Phase 4 1
First in 2010; this study’s year is marked. 2 started in 2012.
This study's enrollment of 15 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 161 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 5 most frequent:
This study is registered under FibroGen, one of the names counted as Kyntra Bio. Under that name alone:
FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
Kyntra Bio has 9 studies filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
1 of the studies testing roxadustat in Kidney Failure, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing roxadustat in Kidney Failure, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study.
This is an open-label, long-term maintenance study of roxadustat anemia therapy in participants with dialysis and non-dialysis CKD who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study. Participants assigned to roxadustat in the previous study will continue to receive the same roxadustat dose and dosing frequency, unless a dose adjustment is required.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
This study's enrollment of 15 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →FibroGen is the lead sponsor of 39 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 14 (100%) have results posted.
Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
Drug: Roxadustat
Oral capsule
Also known as: FG-4592
Change From Baseline in Hb Over Time
Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting. The specific duration over which the participants were assessed was identified as "over time" for the endpoint in the study protocol. Therefore, to be consistent with the endpoint in the study protocol, an individual timepoint was not identified for this primary outcome measure.
Time frame: Baseline, Weeks 8, 24, 48, 72, 96, 120, 144, 168, 192, 216, 240, 252, 264, 288, 312, 336, 360, and 384
Number of Participants With Hb ≥10 g/dL
Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting.
Time frame: Baseline up to Week 384
Number of Participants Receiving Rescue Therapy (Composite of Blood Transfusions, Intravenous [IV] Iron, Erythropoiesis-Stimulating Agent [ESA])
Time frame: Baseline up to Week 385
Mean Weekly Dose of Study Drug Over Time
Weekly dose amount was the actual total dose amounts within a week, windowed by 7-day period from Day 1. The mean weekly dose is presented for selected time periods based on timepoints reported in Outcome Measures 1 and 2.
Time frame: Baseline up to Week 384
Number of Participants With Dose Adjustments up to Week 52
Dose adjustments include dose increases, dose interruptions, and dose reductions.
Time frame: Baseline up to Week 52
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 385
| Milestone | Roxadustat |
|---|---|
| Started | 15 |
| Received at least 1 dose of study drug | 15 |
| Completed | 5 |
| Not completed | 10 |
| Withdrew: Death | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Other than specified | 2 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Other | 1 |
Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting. The specific duration over which the participants were assessed was identified as "over time" for the endpoint in the study protocol. Therefore, to be consistent with the endpoint in the study protocol, an individual timepoint was not identified for this primary outcome measure.
| g/dL | Roxadustat |
|---|---|
| Baseline | 10.05 ± 0.931 |
| Change at Week 8 | 1.26 ± 0.633 |
| Change at Week 24 | 1.58 ± 0.959 |
| Change at Week 48 | 1.94 ± 1.324 |
| Change at Week 72 | 2.54 ± 1.234 |
| Change at Week 96 | 1.18 ± 1.141 |
| Change at Week 120 | 1.61 ± 0.815 |
| Change at Week 144 | 1.96 ± 0.804 |
| Change at Week 168 | 1.40 ± 1.441 |
| Change at Week 192 | 1.02 ± 1.063 |
| Change at Week 216 | 1.34 ± 1.062 |
| Change at Week 240 | 1.02 ± 0.779 |
| Change at Week 264 | 1.63 ± 1.640 |
| Change at Week 288 | 0.00 ± 1.647 |
| Change at Week 312 | 0.23 ± 0.416 |
| Change at Week 336 | 0.70 ± 0.000 |
| Change at Week 360 | -1.20 ± NA |
| Change at Week 384 | -0.40 ± NA |
Hb baseline was defined as the mean of the central laboratory Hb value from the baseline visit at Day 1 (prior to receiving the first dose of study drug in this study), plus any other central lab Hb values within 15 days prior to Day 1 regardless of fasting.
| Participants | Roxadustat |
|---|---|
| Baseline | 9 |
| Week 8 | 13 |
| Week 24 | 13 |
| Week 48 | 13 |
| Week 72 | 11 |
| Week 96 | 7 |
| Week 120 | 8 |
| Week 144 | 7 |
| Week 168 | 5 |
| Week 192 | 5 |
| Week 216 | 5 |
| Week 240 | 5 |
| Week 264 | 4 |
| Week 288 | 3 |
| Week 312 | 3 |
| Week 336 | 2 |
| Week 360 | 1 |
| Week 384 | 1 |
| Participants | Roxadustat |
|---|---|
| Blood Transfusion | 1 |
| IV Iron | 5 |
| ESA | 1 |
| No Rescue Therapy | 8 |
Weekly dose amount was the actual total dose amounts within a week, windowed by 7-day period from Day 1. The mean weekly dose is presented for selected time periods based on timepoints reported in Outcome Measures 1 and 2.
| mg | Roxadustat |
|---|---|
| Week 1-4 | 257.0 ± 140.33 |
| Week 5 - 8 | 252.4 ± 115.26 |
| Week 21 - 24 | 282.3 ± 218.07 |
| Week 41 - 48 | 318.4 ± 216.90 |
| Week 61 - 72 | 236.7 ± 108.57 |
| Week 85 - 96 | 155.9 ± 114.27 |
| Week 109 - 120 | 142.8 ± 105.10 |
| Week 133 - 144 | 140.3 ± 101.03 |
| Week 157 - 168 | 152.2 ± 111.19 |
| Week 181 - 192 | 195.6 ± 184.77 |
| Week 205 - 216 | 209.4 ± 156.13 |
| Week 229 - 240 | 225.7 ± 164.58 |
| Week 253 - 264 | 327.9 ± 169.82 |
| Week 277 - 288 | 324.0 ± 190.75 |
| Week 301 - 312 | 319.2 ± 196.98 |
| Week 325 - 336 | 413.3 ± 180.37 |
| Week 349 - 360 | 389.6 ± 156.15 |
| Week 373 - 384 | 250.0 ± NA |
Dose adjustments include dose increases, dose interruptions, and dose reductions.
| Participants | Roxadustat |
|---|---|
| Participants without Change | 1 |
| Participants with 1 Dose Increase | 5 |
| Participants with 2 Dose Increases | 1 |
| Participants with >2 Dose Increases | 6 |
| Participants with 1 Dose Interruption | 1 |
| Participants with 2 Dose Interruptions | 1 |
| Participants with >2 Dose Interruptions | 0 |
| Participants with 1 Dose Reduction | 2 |
| Participants with 2 Dose Reductions | 8 |
| Participants with >2 Dose Reductions | 2 |
An adverse event (AE) was any untoward medical event in a participant who received study drug whether or not the event is considered drug related. TEAEs were defined as any event that either began or worsened after the first administration of study drug and within 28 days of the last dose. Serious AE criteria included death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed here. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Roxadustat |
|---|---|
| Any TEAEs | 14 |
| Serious TEAEs | 9 |
Collected over Baseline up to Week 385. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roxadustat | 2/15 (13.3%) | 9/15 (60%) | 14/15 (93.3%) |
| Event | Roxadustat |
|---|---|
| Acute myocardial infarctionCardiac disorders | 2/15 |
| Angina pectorisCardiac disorders | 2/15 |
| Atrial fibrillationCardiac disorders | 2/15 |
| Cardiac failure congestiveCardiac disorders | 2/15 |
| PneumoniaInfections and infestations | 2/15 |
| Urinary tract infectionInfections and infestations | 2/15 |
| Chronic kidney diseaseRenal and urinary disorders | 2/15 |
| Hemorrhagic anaemiaBlood and lymphatic system disorders | 1/15 |
| Acute coronary syndromeCardiac disorders | 1/15 |
| Angina unstableCardiac disorders | 1/15 |
| Event | Roxadustat |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 6/15 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/15 |
| Abdominal painGastrointestinal disorders | 3/15 |
| BronchitisInfections and infestations | 3/15 |
| Urinary tract infectionInfections and infestations | 3/15 |
| Viral upper respiratory tract infectionInfections and infestations | 3/15 |
| GoutMetabolism and nutrition disorders | 3/15 |
| HypoglycaemiaMetabolism and nutrition disorders | 3/15 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/15 |
| Vaginal haemorrhageReproductive system and breast disorders | 2/10 |
Participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Roxadustat |
|---|---|
| Mean | 64.6 ± 12.02 |
| Sex: Female, Male(Participants) | Roxadustat |
|---|---|
| Female | 10 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | Roxadustat |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Roxadustat |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 13 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2012 to primary completion in Dec 2019, 90 months.
Results were first posted in Oct 2021, 1 year 9 months after primary completion. A results delay was requested in Jun 2020.
Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 90 months is above that.
Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roxadustat